JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $25
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Tessa Romero maintains an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) and raises the price target from $24 to $25.
June 30, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Edgewise Therapeutics and raises the price target from $24 to $25.
The news of JP Morgan maintaining an Overweight rating and raising the price target for Edgewise Therapeutics is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100